Anti-GD2 Antibody
High-risk neuroblastoma
Clinical Development (phase unspecified)Active
Key Facts
Indication
High-risk neuroblastoma
Phase
Clinical Development (phase unspecified)
Status
Active
Company
About Essential Pharma
Essential Pharma is a private, commercial-stage pharmaceutical company with a unique business model centered on securing the supply of essential medicines at risk of discontinuation and developing treatments for niche, underserved disease areas. With a commercial portfolio reaching approximately 70 countries and a development pipeline initiated by an oncology asset, the company positions itself at the intersection of generic drug sustainability and rare disease innovation. Its strategy combines the reliable revenue of an established product portfolio with the growth potential of targeted clinical development, aiming to transform patient lives in markets often overlooked by larger pharmaceutical firms.
View full company profileTherapeutic Areas
Other High-risk neuroblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| SIMBs + Liposomal Doxorubicin (L-Dox) | Advanced Microbubbles | Pre-clinical |